Prosensa flies after update on Drisapersen

"We are encouraged by these results that suggest that treating earlier in the disease and treating longer shows a delay in the progression of the disease," says Prosensa (RNA +28.6%) CEO Hans Schikan.

The analysis of 96-week extension data shows a 49 meter difference between those on continual treatment and those who had been on a placebo for 48 weeks followed by active drug.

At the moment, the company is presenting further details of the results at the JPMorgan healthcare conference.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs